Claims
- 1. A pharmacuetical liposome composition comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) a substance selected from the group consisting of antiphlogistics, antibiotics, antileishmaniasis agents, antimycotics, antineoplastics and immunomodulators, and a carrier liquid.
- 2. A pharmaceutical liposome composition according to claim 1 comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) a substance selected from the group consisting of diclofenac, pirprofen, mitomycin, cytarabine, dactinomycin, daunorubicin, doxorubicin, etoposide, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide, the disodium salt of N-acetylmuramyl-L-alanyl-D-glutamic acid-(C.sub..gamma.)-L-alanine-2-) 1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide, the sodium salt of N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine, the sodium salt of N-acetyl-D-muramyl-L-alanyl-D-isoglutamine, N-acetyl-D-muramyl-L-alanyl-D-glutamine-.alpha.-n-butyl ester, N.sup..alpha. -(N-acetyl-D-muramyl-L-alanyl-D-isoglutaminyl)-N.sup..epsilon. -stearoyl-L-lysine, 6-0 stearoyl-N-acetylmuramyl-L-alanine-D-isoglutamine and lymphokines, and a carrier liquid buffered to pH 7.2-74.
- 3. A pharmaceutical liposome composition according to claim 1 comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) a substance selected from the group consisting of mitomycin, cytarabine, dactinomycin, daunorubicin, doxorubicin, etoposide, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy) -ethylamide, the sodium salt of N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine, the sodium salt of N-acetyl-D-muramyl-L-alanyl-D-isoglutamine, human gamma-interferon, interleukn 2, and mixtures of substances that are contained in culture filtrates obtained from cultures having human T-lymphocytes from the spleen or peripheral blood after stimulation by antigens or mitogens and that are characterised by a high content of macrophage-activating factor (MAF) and a carrier liquid buffered to pH 7.2-7.4.
- 4. A pharmaceutical liposome composition according to claim 1 comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-octadecenoyl)-3-sn-phosphatidyl choline,
- (c) a compound having immunomodulating action selected from the group consisting of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide, the sodium salt of N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine and the sodium salt of N-acetyl-D-muramyl-L-alanyl-D-isoglutamine and combinations thereof with mixtures of substances that are contained in culture filtrates obtained from cultures having human T-lymphocytes from the spleen or peripheral blood after stimulation by antigens or mitogens and that are characterised by at least a 70% content of MAF, and a carrier liquid buffered to pH 7.2-7.4.
- 5. A pharmeutical liposome composition according to claim 1 comprising
- (a) a synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L--alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide.
- 6. A pharmaceutical liposome composition according to claim 1 comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) recombinant human gamma interferon.
- 7. A pharmaceutical liposome composition according to claim 6 comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) recombinant human gamma interferon having the following amino acid sequence; ##STR8##
- 8. A pharmaceutical liposome composition according to claim 6 comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) recombinant human gamma interferon having the following amino acid sequence; ##STR9##
- 9. A pharmaceutical lyophilisate composition comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) a substance selected from the group consisting of antiphlogistics, antibiotics, antileishmaniasis agents, antimycotics, antineoplastics and immunomodulators.
- 10. A pharmaceutical lyophilisate composition according to claim 9 comprising
- (a) synthetic, substantially pure sodium 1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine,
- (b) synthetic, substantially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline, and
- (c) N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide.
Priority Claims (1)
Number |
Date |
Country |
Kind |
4951/84 |
Oct 1984 |
CHX |
|
Parent Case Info
This application is a continuation of application Ser. No. 169,085, filed Mar. 17, 1988, and now abandoned, which is a continuation of Ser. No. 787,222, filed Oct. 15, 1985, now abandoned.
US Referenced Citations (13)
Foreign Referenced Citations (6)
Number |
Date |
Country |
088946 |
Sep 1983 |
EPX |
099068 |
Jan 1984 |
EPX |
147741 |
Jul 1985 |
EPX |
2647395 |
Apr 1978 |
DEX |
WO8400367 |
Feb 1984 |
WOX |
1523965 |
Sep 1978 |
GBX |
Non-Patent Literature Citations (2)
Entry |
CS 200: 205314k (1984). |
CA 89: 42466z (1978). |
Continuations (2)
|
Number |
Date |
Country |
Parent |
169085 |
Mar 1988 |
|
Parent |
787222 |
Oct 1985 |
|